Marksans Pharma Ltd announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution

Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) announced that UK MHRA has granted Market Authorisation to the Company's wholly owned subsidiary Relonchem Limited for Fluoxetine 20mg/5ml Oral Solution.

Therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders.

The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK.

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 67.15 as compared to the previous close of Rs. 66.05. The total number of shares traded during the day was 1190815 in over 5015 trades.

The stock hit an intraday high of Rs. 69.60 and intraday low of 65.75. The net turnover during the day was Rs. 81436800.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 UKMHRA MarketAuthorisation Relonchem Fluxotine OralSolution